Soluble CD14: Role in atopic disease and recurrent infections, including otitis media

Current Allergy and Asthma Reports

Volumn 7, Issue 6, 2007, Pages 436-443

  Carlsen, Karin C Løodrup ^a   Granum, Berit ^b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD14 ANTIGEN; IMMUNOGLOBULIN E; INTERLEUKIN 1; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; TOBACCO SMOKE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PANCREATITIS; ALLERGIC DISEASE; ANTIBODY RESPONSE; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ASTHMATIC STATE; ATOPY; B LYMPHOCYTE; BACTERIAL COLONIZATION; BODY FLUID; BREAST MILK; CELLULAR IMMUNITY; CHILDHOOD DISEASE; CHRONIC LIVER DISEASE; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DUODENUM ULCER; DYSPEPSIA; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; FETUS DEVELOPMENT; GAUCHER DISEASE; GENE LOCUS; GENETIC POLYMORPHISM; GENOTYPE; GRAM NEGATIVE INFECTION; HEREDITY; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOMODULATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MENINGOCOCCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OTITIS MEDIA; PRENATAL EXPOSURE; PROMOTER REGION; RECURRENT INFECTION; REGULATORY MECHANISM; RESPIRATORY TRACT DISEASE; REVIEW; SEX DIFFERENCE; SMOKING; STOMACH ULCER; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; UMBILICAL CORD BLOOD;

EID: 35448960453     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-007-0067-2     Document Type: Review

References (75)

1. Labeta MO, Durieux JJ, Fernandez N, et al.: Release from a human monocyte-like cell line of two different soluble forms of the lipopolysaccharide receptor, CD14. Eur J Immunol 1993, 23:2144-2151.
2. Blumenthal MN: New thoughts regarding the genetics of atopy. Am J Respir Crit Care Med 2004, 169:555-556.
3. Kitchens RL, Thompson PA, Viriyakosol S, et al.: Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest 2001, 108:485-493.
4. Lien E, Aukrust P, Sundan A, et al.: Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1(HIV-1) infection: correlation to disease progression and clinical events. Blood 1998, 92:2084-2092.
5. Wright SD, Ramos RA, Tobias PS, et al.: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249:1431-1433.
6. Wurfel MM, Hailman E, Wright SD: Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Exp Med 1995, 181:1743-1754.
7. Bas S, Gauthier BR, Spenato U, et al.: CD14 is an acute-phase protein. J Immunol 2004, 172:4470-4479.
8. Arias MA, Rey Nores JE, Vita N, et al.: Cutting edge: human B cell function is regulated by interaction with soluble CD14: opposite effects on IgG1 and IgE production. J Immunol 2000, 164:3480-3486.
9. Filipp D, Alizadeh-Khiavi K, Richardson C, et al.: Soluble CD14 enriched in colostrum and milk induces B cell growth and differentiation. Proc Natl Acad Sci U S A 2001, 98:603-608.
10. Rey Nores JE, Bensussan A, Vita N, et al.: Soluble CD14 acts as a negative regulator of human T cell activation and function. Eur J Immunol 1999, 29:265-276.
11. Vercelli D, Baldini M, Stern D, et al.: CD14: a bridge between innate immunity and adaptive IgE responses. J Endotoxin Res 2001, 7:45-48.
12. Dentener MA, Bazil V, Von Asmuth EJ, et al.: Involvement of CD14 in lipopolysaccharide-induced tumor necrosis factor-alpha, IL-6 and IL-8 release by human monocytes and alveolar macrophages. J Immunol 1993, 150:2885-2891.
13. Antal-Szalmas P: Evaluation of CD14 in host defence. Eur J Clin Invest 2000, 30:167-179.
14. Yu B, Hailman E, Wright SD: Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of phospholipids. J Clin Invest 1997, 99:315-324.
15. Pugin J, Heumann ID, Tomasz A, et al.: CD14 is a pattern recognition receptor. Immunity 1994, 1:509-516.
16. Lauener RP, Goyert SM, Geha RS, Vercelli D: Interleukin 4 down-regulates the expression of CD14 in normal human monocytes. Eur J Immunol 1990, 20:2375-2381.
17. Blais DR, Harrold J, Altosaar I: Killing the messenger in the nick of time: persistence of breast milk sCD14 in the neonatal gastrointestinal tract. Pediatr Res 2006, 59:371-376.
18. Jones CA, Holloway JA, Popplewell EJ, et al.: Reduced soluble CD14 levels in amniotic fluid and breast milk are associated with the subsequent development of atopy, eczema, or both. J Allergy Clin Immunol 2002, 109:858-866.
19. Rothenbacher D, Weyermann M, Beermann C, Brenner H: Breastfeeding, soluble CD14 concentration in breast milk and risk of atopic dermatitis and asthma in early childhood: birth cohort study. Clin Exp Allergy 2005, 35:1014-1021.
20. Snijders BE, Damoiseaux JG, Penders J, et al.: Cytokines and soluble CD14 in breast milk in relation with atopic manifestations in mother and infant (KOALA study). Clin Exp Allergy 2006, 36:1609-1615.
21. Espinoza J, Chaiworapongsa T, Romero R, et al.: Evidence of participation of soluble CD14 in the host response to microbial invasion of the amniotic cavity and intra-amniotic inflammation in term and preterm gestations. J Matern Fetal Neonatal Med 2002, 12:304-312.
22. Roos T, Martin TR, Ruzinski JT, et al.: Lipopolysaccharide binding protein and soluble CD14 receptor protein in amniotic fluid and cord blood in patients at term. Am J Obstet Gynecol 1997, 177:1230-1237.
23. Cauwels A, Frei K, Sansano S, et al.: The origin and function of soluble CD14 in experimental bacterial meningitis. J Immunol 1999, 162:4762-4772.
24. Dubin W, Martin TR, Swoveland P, et al.: Asthma and endotoxin: lipopolysaccharide-binding protein and soluble CD14 in bronchoalveolar compartment. Am J Physiol 1996, 270(5 Pt 1):L736-L744.
25. Hoheisel G, Zheng L, Teschler H, et al.: Increased soluble CD14 levels in BAL fluid in pulmonary tuberculosis. Chest 1995, 108:1614-1616.
26. Lin B, Noring R, Steere AC, et al.: Soluble CD14 levels in the serum, synovial fluid, and cerebrospinal fluid of patients with various stages of Lyme disease. J Infect Dis 2000, 181:1185-1188.
27. Nockher WA, Wick M, Pfister HW: Cerebrospinal fluid levels of soluble CD14 in inflammatory and non-inflammatory diseases of the CNS: upregulation during bacterial infections and viral meningitis. J Neuroimmunol 1999, 101:161-169.
28. Striz I, Zheng L, Wang YM, et al.: Soluble CD14 is increased in bronchoalveolar lavage of active sarcoidosis and correlates with alveolar macrophage membrane-bound CD14. Am J Respir Crit Care Med 1995, 151(2 Pt 1):544-547.
29. Ward C, Waiters EH, Zheng L, et al.: Increased soluble CD14 in bronchoalveolar lavage fluid of stable lung transplant recipients. Eur Respir J 2002, 19:472-478.
30. Zdolsek HA, Jenmalm MC: Reduced levels of soluble CD14 in atopic children. Clin Exp Allergy 2004, 34:532-539.
31. Lødrup Carlsen KC, Lovik M, Granum B, et al.: Soluble CD14 at 2 yr of age: gender-related effects of tobacco smoke exposure, recurrent infections and atopic diseases. Pediatr Allergy Immunol 2006, 17:304-312.
32. O'Donnell AR, Toelle BG, Marks GB, et al.: Age-specific relationship between CD14 and atopy in a cohort assessed from age 8 to 25 years. Am J Respir Crit Care Med 2004, 169:615-622.
33. Yaegashi Y, Shirakawa K, Sato N, et al.: Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother 2005, 11:234-238.
34. Rahman SH, Salter G, Holmfield JH, et al.: Soluble CD14 receptor expression and monocyte heterogeneity but not the C-260T CD14 genotype are associated with severe acute pancreatitis. Crit Care Med 2004, 32:2457-2463.
35. Meiler C, Muhlbauer M, Johann M, et al.: Different effects of a CD14 gene polymorphism on disease outcome in patients with alcoholic liver disease and chronic hepatitis C infection. World J Gastroenterol 2005, 11:6031-6037.
36. Hollak CE, Evers L, Aerts JM, van Oers MH: Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 1997, 23:201-212.
37. Nockher WA, Wigand R, Schoeppe W, Scherberich JE: Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus. Clin Exp Immunol 1994, 96:15-19.
38. Fernandez-Real JM, Lopez-Bermejo A, Castro A, et al.: Opposite relationship between circulating soluble CD14 concentration and endothelial function in diabetic and nondiabetic subjects. Thromb Haemost 2005, 94:615-619.
39. Karhukorpi J, Yan Y, Niemela S, et al.: Effect of CD14 promoter polymorphism and H. pylori infection and its clinical outcomes on circulating CD14. Clin Exp Immunol 2002, 128:326-332.
40. Garty BZ, Monselise Y, Nitzan M: Soluble CD14 in children with status asthmaticus. Isr Med Assoc J 2000, 2:104-107.
41. Nielsen HG, Lyberg T: Long-distance running modulates the expression of leucocyte and endothelial adhesion molecules. Stand J Immunol 2004, 60:356-362.
42. Martin AC, Laing IA, Zhang G, et al.: CD14 C-159T and early infection with Pseudomonas aeruginosa in children with cystic fibrosis. Respir Res 2005, 6:63.
43. Guerra S, Lohman IC, Halonen M, et al.: Reduced interferon gamma production and soluble CD14 levels in early life predict recurrent wheezing by 1 year of age. Am J Respir Crit Care Med 2004, 169:70-76.
44. Wuthrich B, Kagi MK, Joller-Jemelka H: Soluble CD14 but not interleukin-6 is a new marker for clinical activity in atopic dermatitis. Arch Dermatol Res 1992, 284:339-342.
45. Martin AC, Laing IA, Khoo SK, et al.: Acute asthma in children: relationships among CD14 and CC16 genotypes, plasma levels, and severity. Am J Respir Crit Care Med 2006, 173:617-622.
46. Virchow JC Jr, Julius P, Matthys H, et al.: CD14 expression and soluble CD14 after segmental allergen provocation in atopic asthma. Eur Respir J 1998, 11:317-323.
47. Holmlund U, Hoglind A, Larsson AK, et al.: CD14 and development of atopic disease at 2 years of age in children with atopic or non-atopic mothers. Clin Exp Allergy 2003, 33:455-463.
48. Alexis N, Eldridge M, Reed W, et al.: CD14-dependent airway neutrophil response to inhaled LPS: role of atopy. J Allergy Clin Immunol 2001, 107:31-35.
49. Koppelman GH, Reijmerink NE, Colin SO, et al.: Association of a promoter polymorphism of the CD14 gene and atopy. Am J Respir Crit Care Med 2001, 163:965-969.
50. Keskin O, Birben E, Sackesen C, et al.: The effect of CD14-c159T genotypes on the cytokine response to endotoxin by peripheral blood mononuclear cells from asthmatic children. Ann Allergy Asthma Immunol 2006, 97:321-328.
51. LeVan TD, Guerra S, Klimecki W, et al.: The impact of CD14 polymorphisms on the development of soluble CD14 levels during infancy. Genes Immun 2006, 7:77-80.
52. Holt PG, Sly PD: Interactions between respiratory tract infections and atopy in the aetiology of asthma. Eur Respir J 2002, 19:538-545.
53. Wennergren G, Kristjansson S: Relationship between respiratory syncytial virus bronchiolitis and future obstructive airway diseases. Eur Respir J 2001, 18:1044-1058.
54. Matricardi PM, Ronchetti R: Are infections protecting from atopy? Curr Opin Allergy Clin Immunol 2001, 1:413-419.
55. Kurt-Jones EA, Popova L, Kwinn L, et al.: Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000, 1:398-401.
56. Juntti H, Kokkonen J, Dunder T, et al.: Serum concentrations of interferon-gamma and intercellular adhesion molecule-1 eight years after an early respiratory syncytial virus infection. Clin Exp Allergy 2005, 35:59-63.
57. Faden H: The microbiologic and immunologic basis for recurrent otitis media in children. Eur J Pediatr 2001, 160:407-413.
58. Yang IA, Savarimuthu S, Kim ST, et al.: Gene-environmental interaction in asthma. Curr Opin Allergy Clin Immunol 2007, 7:75-82.
59. Jackola DR, Basu S, Liebeler CL, et al.: CD14 promoter polymorphisms in atopic families: implications for modulated allergen-specific immunoglobulin E and G1 responses. Int Arch Allergy Immunol 2006, 139:217-224.
60. Gereda JE, Klinnert MD, Price MR, et al.: Metropolitan home living conditions associated with indoor endotoxin levels. J Allergy Clin Immunol 2001, 107:790-796.
61. Lapa e Silva JR, Possebon DS, Lefort J, Vargaftig BB: Endotoxins, asthma, and allergic immune responses. Toxicology 2000, 152:31-35.
62. Cook DG, Strachan DP: Health effects of passive smoking-10: summary of effects of parental smoking on the respiratory health of children and implications for research. Thorax 1999, 54:357-366.
63. Strachan DP, Cook DG: Health effects of passive smoking. 4. Parental smoking, middle ear disease and adenotonsillectomy in children. Thorax 1998, 53:50-56.
64. Nouri-Shirazi M, Guinet E: Evidence for the immunosuppressive role of nicotine on human dendritic cell functions. Immunology 2003, 109:365-373.
65. Skold CM, Lundahl J, Hallden G, et al.: Chronic smoke exposure alters the phenotype pattern and the metabolic response in human alveolar macrophages. Clin Exp Immunol 1996, 106:108-113.
66. Hockertz S, Emmendorffer A, Scherer G, et al.: Acute effects of smoking and high experimental exposure to environmental tobacco smoke (ETS) on the immune system. Cell Biol Toxicol 1994, 10:177-190.
67. Choudhry S, Avila PC, Nazario S, et al.: CD14 tobacco gene-environment interaction modifies asthma severity and immunoglobulin E levels in Latinos with asthma. Am J Respir Crit Care Med 2005, 172:173-182.
68. Tan CY, Chen YL, Wu LS, et al.: Association of CD14 promoter polymorphisms and soluble CD14 levels in mite allergen sensitization of children in Taiwan. J Hum Genet 2006, 51:59-67.
69. Savilahti E, Siltanen M, Kajosaari M, et al.: IgA antibodies, TGF-beta1 and -beta2, and soluble CD14 in the colostrum and development of atopy by age 4. Pediatr Res 2005, 58:1300-1305.
70. Laitinen K, Hoppu U, Hamalainen M, et al.: Breast milk fatty acids may link innate and adaptive immune regulation: analysis of soluble CD14, prostaglandin E2, and fatty acids. Pediatr Res 2006, 59:723-727.
71. Vidal K, Donnet-Hughes A, Granato D: Lipoteichoic acids from Lactobacillus johnsonii strain La1 and Lactobacillus acidophilus strain La10 antagonize the responsiveness of human intestinal epithelial HT29 cells to lipopolysaccharide and gram-negative bacteria. Infect Immun 2002, 70:2057-2064.
72. Labeta MO, Vidal K, Nores JE, et al.: Innate recognition of bacteria in human milk is mediated by a milk-derived highly expressed pattern recognition receptor, soluble CD14. J Exp Med 2000, 191:1807-1812.
73. Baveye S, Elass E, Fernig DG, et al.: Human lactoferrin interacts with soluble CD14 and inhibits expression of endothelial adhesion molecules, E-selectin and ICAM-1, induced by the CD14-lipopolysaccharide complex. Infect Immun 2000, 68:6519-6525.
74. Lundell AC, Andersson K, Josefsson E, et al.: Soluble CD14 and CD83 from human neonatal antigen-presenting cells are inducible by commensal bacteria and suppress allergen-induced human neonatal Th2-differentiation. Infect Immun 2007, 75:4097-4104.
75. Dunstan JA, Roper J, Mitoulas L, et al.: The effect of supplementation with fish oil during pregnancy on breast milk immunoglobulin A, soluble CD14, cytokine levels and fatty acid composition. Clin Exp Allergy 2004, 34:1237-1242.